Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has been given a consensus rating of “Buy” by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $33.86.

A number of research firms have recently commented on XNCR. StockNews.com downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company reduced their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th.

Institutional Trading of Xencor

Several institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP increased its holdings in Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock worth $55,218,000 after purchasing an additional 1,827,883 shares during the period. BVF Inc. IL grew its position in shares of Xencor by 169.3% during the 4th quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock worth $52,596,000 after buying an additional 1,438,760 shares in the last quarter. Nuveen Asset Management LLC increased its stake in shares of Xencor by 452.4% during the fourth quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company’s stock valued at $19,236,000 after buying an additional 685,557 shares during the period. Finepoint Capital LP bought a new stake in shares of Xencor in the fourth quarter valued at about $15,167,000. Finally, Vanguard Group Inc. lifted its stake in Xencor by 5.5% in the fourth quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock worth $184,239,000 after acquiring an additional 418,040 shares during the period.

Xencor Stock Up 1.9 %

XNCR opened at $9.70 on Friday. The firm’s 50 day simple moving average is $12.33 and its two-hundred day simple moving average is $18.74. The company has a market capitalization of $683.48 million, a PE ratio of -3.03 and a beta of 0.90. Xencor has a 1-year low of $7.16 and a 1-year high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The company had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. As a group, equities analysts forecast that Xencor will post -3.68 EPS for the current year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.